JP2005523318A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523318A5
JP2005523318A5 JP2003585745A JP2003585745A JP2005523318A5 JP 2005523318 A5 JP2005523318 A5 JP 2005523318A5 JP 2003585745 A JP2003585745 A JP 2003585745A JP 2003585745 A JP2003585745 A JP 2003585745A JP 2005523318 A5 JP2005523318 A5 JP 2005523318A5
Authority
JP
Japan
Prior art keywords
virus
viruses
treatment
antigen
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003585745A
Other languages
English (en)
Japanese (ja)
Other versions
JP4801880B2 (ja
JP2005523318A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/003994 external-priority patent/WO2003088994A2/en
Publication of JP2005523318A publication Critical patent/JP2005523318A/ja
Publication of JP2005523318A5 publication Critical patent/JP2005523318A5/ja
Application granted granted Critical
Publication of JP4801880B2 publication Critical patent/JP4801880B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003585745A 2002-04-19 2003-04-16 新生仔予防接種用変異ワクシニアウイルスアンカラ Expired - Lifetime JP4801880B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200590 2002-04-19
DKPA200200590 2002-04-19
PCT/EP2003/003994 WO2003088994A2 (en) 2002-04-19 2003-04-16 Modified vaccinia virus ankara for the vaccination of neonates

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010028940A Division JP2010120955A (ja) 2002-04-19 2010-02-12 新生仔予防接種用変異ワクシニアウイルスアンカラ
JP2011115564A Division JP5690214B2 (ja) 2002-04-19 2011-05-24 新生仔予防接種用変異ワクシニアウイルスアンカラ

Publications (3)

Publication Number Publication Date
JP2005523318A JP2005523318A (ja) 2005-08-04
JP2005523318A5 true JP2005523318A5 (OSRAM) 2006-06-08
JP4801880B2 JP4801880B2 (ja) 2011-10-26

Family

ID=29225556

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003585745A Expired - Lifetime JP4801880B2 (ja) 2002-04-19 2003-04-16 新生仔予防接種用変異ワクシニアウイルスアンカラ
JP2010028940A Pending JP2010120955A (ja) 2002-04-19 2010-02-12 新生仔予防接種用変異ワクシニアウイルスアンカラ
JP2011115564A Expired - Lifetime JP5690214B2 (ja) 2002-04-19 2011-05-24 新生仔予防接種用変異ワクシニアウイルスアンカラ
JP2014257263A Pending JP2015061876A (ja) 2002-04-19 2014-12-19 新生仔予防接種用変異ワクシニアウイルスアンカラ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2010028940A Pending JP2010120955A (ja) 2002-04-19 2010-02-12 新生仔予防接種用変異ワクシニアウイルスアンカラ
JP2011115564A Expired - Lifetime JP5690214B2 (ja) 2002-04-19 2011-05-24 新生仔予防接種用変異ワクシニアウイルスアンカラ
JP2014257263A Pending JP2015061876A (ja) 2002-04-19 2014-12-19 新生仔予防接種用変異ワクシニアウイルスアンカラ

Country Status (23)

Country Link
US (3) US7897156B2 (OSRAM)
EP (4) EP2204179A3 (OSRAM)
JP (4) JP4801880B2 (OSRAM)
KR (2) KR20110017904A (OSRAM)
CN (1) CN100540051C (OSRAM)
AT (1) ATE366586T2 (OSRAM)
AU (1) AU2003239805B2 (OSRAM)
BR (1) BR0309339A (OSRAM)
CA (1) CA2478009C (OSRAM)
CY (1) CY1106848T1 (OSRAM)
DE (1) DE60314823T3 (OSRAM)
DK (1) DK1420822T4 (OSRAM)
EA (1) EA011233B1 (OSRAM)
ES (1) ES2288609T5 (OSRAM)
IL (1) IL163701A0 (OSRAM)
MX (1) MXPA04010353A (OSRAM)
NO (1) NO336348B1 (OSRAM)
NZ (2) NZ547776A (OSRAM)
PL (1) PL220781B1 (OSRAM)
PT (1) PT1420822E (OSRAM)
SG (1) SG173216A1 (OSRAM)
UA (1) UA85371C2 (OSRAM)
WO (1) WO2003088994A2 (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
AU3163902A (en) * 2000-11-23 2002-06-03 Bavarian Nordic Res Inst As Modified vaccinia ankara virus variant
WO2003088994A2 (en) * 2002-04-19 2003-10-30 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
AU2003294248A1 (en) * 2002-11-07 2004-06-03 Aventis Pasteur, Inc. Smallpox vaccine regimen
HUE030037T2 (en) * 2005-02-23 2017-04-28 Bavarian Nordic As Use of modified anemic virus for rapid induction of immunity against gluten virus or other agents
EP1835031A1 (en) * 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
EP2303322A1 (en) * 2008-06-20 2011-04-06 Bavarian Nordic A/S Recombinant modified vaccinia virus measles vaccine
ES2617926T3 (es) * 2010-11-05 2017-06-20 Bavarian Nordic A/S Modulación de respuestas inmunitarias por la proteína K4 poxvírica
US9821054B2 (en) 2011-03-11 2017-11-21 Turnstone Limited Partnership Method of vaccination comprising a histone deacetylase inhibitor
WO2014037124A1 (en) * 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
AU2014231229A1 (en) * 2013-03-15 2015-09-17 Bavarian Nordic A/S Single high dose of MVA induces a protective immune response in neonates and infants
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
ES3049406T3 (en) 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
UA113442C2 (xx) 2015-01-27 2017-01-25 Ентеросорбент
EP3261669B1 (en) * 2015-02-25 2022-08-03 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
CN108025048B (zh) 2015-05-20 2022-10-25 博德研究所 共有的新抗原
TWI750122B (zh) 2015-06-09 2021-12-21 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
WO2017147553A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
IL261321B2 (en) 2016-02-25 2023-12-01 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
AU2019339535B2 (en) 2018-09-15 2025-11-20 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
CA3161800A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4452305A1 (en) * 2021-12-23 2024-10-30 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914408A (en) * 1973-10-12 1975-10-21 Univ Nebraska Vaccine for neonatal calf diarrhea
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
JPS6035647A (ja) † 1983-08-09 1985-02-23 Nippon Denso Co Ltd アンチスキツド制御装置
US6248333B1 (en) * 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5843456A (en) * 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5403582A (en) * 1993-01-21 1995-04-04 Nippon Zeon Co., Ltd. Vaccine comprising fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus
US5405772A (en) * 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US6190655B1 (en) * 1993-12-03 2001-02-20 Immunex Corporation Methods of using Flt-3 ligand for exogenous gene transfer
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2243937T3 (es) * 1994-04-29 2005-12-01 Baxter Healthcare S.A. Poxvirus recombinados en regiones esenciales con la ayuda de polinucleotidos extraños.
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
AP964A (en) 1996-02-21 2001-05-11 Julianna Lisziewicz Methods and compositions for protective and therapeutic genetic immunisation.
ID19548A (id) † 1996-09-24 1998-07-23 Bavarian Nordic Res Inst As Virus mva rekombinan yang mengekspresikan antigen-antigen virus demam dan penggunaan daripadanya dalam vaksin-vaksin
AU5091898A (en) * 1996-10-25 1998-05-15 Wistar Institute Of Anatomy And Biology, The Method of vaccinating infants against infections
US6204250B1 (en) * 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
GB0023203D0 (en) * 2000-09-21 2000-11-01 Isis Innovation Vaccination method
GB9711957D0 (en) † 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
AU3910097A (en) 1997-08-05 1999-03-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Live recombinant vaccine comprising inefficiently or non-replicating vir us
EP1160323A1 (en) 1998-11-18 2001-12-05 Oxford Biomedica (UK) Limited 5T4 tumour-associated antigen for use in tumour immunotherapy
GB2370571B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd A modified 5t4 antigen
UA84388C2 (ru) * 2000-03-14 2008-10-27 Бавариан Нордик А/С Измененный штамм модифицированного вируса виспы крупного рогатого скота ankara (mva)
PL360096A1 (en) 2000-05-24 2004-09-06 Merial Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
AU2001268452B2 (en) * 2000-06-15 2006-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A recombinant non-replicating virus expressing GM-CSF and uses thereof to enhance immune responses
AU2001270631B2 (en) * 2000-07-11 2005-07-07 Bayer Aktiengesellschaft Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
DE10042598A1 (de) * 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
AU3163902A (en) 2000-11-23 2002-06-03 Bavarian Nordic Res Inst As Modified vaccinia ankara virus variant
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
WO2003048184A2 (en) * 2001-12-04 2003-06-12 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
WO2003088994A2 (en) * 2002-04-19 2003-10-30 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
EA007811B1 (ru) * 2002-05-16 2007-02-27 Бавариан Нордик А/С Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)
BRPI0414224A (pt) * 2003-09-10 2006-12-26 Ra Brands Llc método de acabamento de uma nervura para uma arma de fogo
CA2545164C (en) * 2003-11-12 2016-11-29 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Recombinant vectors expressing mucin and carcinoembryoinic antigen
US7618980B2 (en) * 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
EP1925318A1 (en) 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8613936B2 (en) * 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements

Similar Documents

Publication Publication Date Title
JP2005523318A5 (OSRAM)
JP2018536433A5 (OSRAM)
US9707285B2 (en) Vaccination methods
JP2006501825A5 (OSRAM)
JP2014503206A5 (OSRAM)
JP2020516264A5 (OSRAM)
FI3371316T3 (fi) Rokotteita hepatiitti b -virusta vastaan
JP2016513115A5 (OSRAM)
JP2016128513A5 (OSRAM)
EP2391383B1 (en) Codon-optimized hepatitis b virus core antigen (hbcag)
MX2020000221A (es) Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas.
JP2014502156A5 (OSRAM)
RU2019107976A (ru) Композиция вакцины
JP2012525410A5 (OSRAM)
JP2017510262A5 (OSRAM)
WO2000061737A3 (en) Production of attenuated negative stranded RNA virus vaccines
JPWO2012053646A1 (ja) ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター
WO2006037038B1 (en) Optimized vaccines to provide protection against ebola and other viruses
WO2003046506A3 (en) Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies
WO2014063601A1 (zh) 诱导肿瘤特异性免疫的疫苗及其应用
Saeedi et al. Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice
Helmold et al. Advancing ORFV‐Based Therapeutics to the Clinical Stage
CN1665921A (zh) 用于免疫治疗的腺病毒载体
JP2009501012A5 (OSRAM)
CN106928372A (zh) 乙肝重组抗原及其表达基因、构建方法、病毒样颗粒及其制备方法、应用与疫苗